Condition: T-Cell Leukemia/Lymphoma, Adult · T-cell Leukemia/Lymphoma · T-cell Leukemia · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
This description comes directly from the study's public registry record.
Steven Horwitz, MD · 646-608-2680 · horwitzs@MSKCC.ORG
Alison Moskowitz, MD · 646-608-3726 · moskowia@mskcc.org
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering at Basking Ridge (All protocol activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All protocol activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (All protocol activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (All protocol activities) | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06698003